Most Read Articles
Roshini Claire Anthony, Yesterday

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
17 May 2018
A study examining the validity of baseline cardiac screening for left ventricular ejection fraction (EF) has found that only two (1.1 percent) of the screened patients have an abnormal EF (<50 percent). These patients have received doxorubicin (anthracycline) chemotherapy despite a compromised EF.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Risk of VTE higher in patients with primary Sjögren syndrome

31 Aug 2017

Population-based evidence shows a substantially increased risk of venous thromboembolism (VTE) among patients with primary Sjögren syndrome (pSS), especially within the first year after SS diagnosis.

Researchers created a study cohort of all patients with incident SS using a population database that includes all residents of British Columbia, Canada, and up to 10 controls from the general population matched for age, sex and entry time to estimate the future risk and time trends of VTE in individuals with newly diagnosed PSS.

Incidence rates (IRs) of pulmonary embolism (PE), deep vein thrombosis (DVT) and VTE were compared between the two groups according to SS disease duration. Hazard ratio (HR) was also calculated, adjusting for confounders.

Of the 1,175 incident pSS cases (mean age 56.7 years; 87.6 percent women), the respective IRs of PE, DVT and VTE were 3.9, 2.8 and 5.2 per 1,000 person-years. The corresponding rates among controls were 0.9, 0.8 and 1.4 per 1,000 person-years.

In comparison with non-SS individuals, the multivariable HR among SS cases was 4.07 (95 percent CI, 2.04 to 8.09) for PE, 2.80 (1.27 to 6.17) for DVT and 2.92 (1.66 to 5.16) for VTE. The HR matched for age, sex and entry for VTE (8.29; 2.57 to 26.77), PE (4.72; 1.13 to 19.73) and DVT (7.34; 2.80 to 19.25) were highest during the first year after SS diagnosis.

According to researchers, further studies into the involvement of monitoring and prevention of VTE in SS may be warranted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, Yesterday

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
17 May 2018
A study examining the validity of baseline cardiac screening for left ventricular ejection fraction (EF) has found that only two (1.1 percent) of the screened patients have an abnormal EF (<50 percent). These patients have received doxorubicin (anthracycline) chemotherapy despite a compromised EF.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.